GlassScriptPhysician profile
Matthew D Cheng
NPI 1801845524
$14,812.18
in general payments reported to CMS, 2019-2025
42 companies · $2,651 in 2025
The $2,651 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,583 · 2020: $1,243 · 2021: $1,974 · 2022: $2,341 · 2023: $2,520 · 2024: $2,500 · 2025: $2,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,359 · Education: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,358.70 |
| Education | $312.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,816.65 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $2,497.12 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,454.46 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $1,129.42 | 2019-2025 | Dupixent |
| Genzyme Corporation | $907.79 | 2019-2025 | |
| United Therapeutics Corporation | $618.41 | 2021-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $606.46 | 2021-2025 | Opsumit, Uptravi |
| Jazz Pharmaceuticals INC. | $387.06 | 2021-2025 | Xywav |
| Grifols USA, LLC | $353.87 | 2019-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $314.52 | 2019-2024 | Xolair |
| Amgen INC. | $305.91 | 2022-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $257.87 | 2020-2022 | |
| Mylan Specialty L.P. | $233.06 | 2019-2024 | Yupelri |
| Pfizer INC. | $229.66 | 2020-2025 | |
| Pulmonx Corporation | $203.40 | 2024-2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $202.45 | 2020-2025 | Glassia, Aralast |
| Sanofi-Aventis U.S. LLC | $188.26 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $184.35 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $165.41 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $164.60 | 2022-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $153.57 | 2019-2022 | |
| Inspire Medical Systems, INC. | $147.40 | 2024 | Inspire |
| Electromed, INC. | $132.18 | 2024-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $130.57 | 2019-2023 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $129.61 | 2021-2024 | Opdivo |
| Ethicon INC. | $113.72 | 2022 | |
| Insmed, INC. | $110.21 | 2021-2025 | Arikayce, Brinsupri |
| Intuitive Surgical, INC. | $97.83 | 2023 | Da Vinci Surgical System |
| Viatris Specialty LLC | $95.29 | 2025 | Yupelri |
| Csl Behring | $84.36 | 2019-2024 | Kcentra |
| Baxter Healthcare | $74.15 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Verona Pharma, INC. | $57.30 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $50.72 | 2024 | Sunosi |
| Azurity Pharmaceuticals, INC. | $39.94 | 2025 | Alvesco |
| Harmony Biosciences LLC | $34.02 | 2022-2025 | |
| Philips North America LLC | $31.12 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Shionogi INC | $20.85 | 2022 | |
| Advanced Respiratory, INC | $20.38 | 2021 | |
| Shire North American Group INC | $17.83 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $17.41 | 2025 | Lumryz |
| Gilead Sciences, INC. | $17.29 | 2021 | |
| Phadia US INC. | $15.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.